FDA Approves Sevenfact for Hemophilia

The FDA approved Laboratoire Francais du Fractionnement et des Biotechnologies’ Sevenfact blood coagulation factor for treating bleeding episodes in patients 12 years and older with hemophilia A or B.

The approval was based on results from a clinical trial of 27 patients in which 86 percent of mild or moderate bleeding episodes were successfully treated.

Sevenfact’s active ingredient is an analog of human coagulation factor FVII expressed in the mammary glands of genetically engineered rabbits.